Golden
Aglaia Biomedical Ventures

Aglaia Biomedical Ventures

Aglaia is an oncology specialist investor which selects and matures early-stage breakthrough inventions.

All edits

Edits on 17 Jun 2019
Carla Faraguna
Carla Faraguna edited on 17 Jun 2019 9:25 pm
Edits made to:
Article (+38 characters)

Article

Aglaia Biomedical Ventures B.V. is a private equity and venture capital firm specializing in investments in incubation, startup, early stage, private investment in public equity (PIPEs), bridge financing, companies.

Edits on 22 Apr 2019
Carla Faraguna
Carla Faraguna edited on 22 Apr 2019 6:12 pm
Edits made to:
Article (-129 characters)

Article

Aglaia is committed to defining the strategic directions of the companies it invests in, together with innovators and entrepreneurs. It offers portfolio companies support in designing research and development plans, ranging from early screening and animal feasibility studies through clinical studies.

Edits on 3 Apr 2019
Golden AI
Golden AI edited on 3 Apr 2019 11:50 am
Edits made to:
Infobox (+1 properties)
Edits on 11 Feb 2019
Sergiu Miron
Sergiu Miron edited on 11 Feb 2019 9:21 pm
Edits made to:
Article (+213/-228 characters)

Article



The company, which currently has three funds under management, differs from other funds in that it focuses exclusively on oncology, as well as by getting involved at an early stage of technological development and through its hands-on management and efficient allocation of capital.



Aglaia has a revenue of $1.4Million , focuses on oncology and invests in novel tools and technologies as well as components of contemporary drug development.

...



...

Through its Oncology Funds I and II, Aglaia has invested in 12 early stage companies, 6 of which were founded by Aglaia. The Aglaia team has been involved in the development of more than 100 oncology products.



Through its Oncology Funds I and II, Aglaia has invested in 12 early stage companies, 6 of which were founded by Aglaia. The Aglaia team has been involved in the development of more than 100 oncology products. Aglaia's goal is to have continuous strategic and operational involvement with portfolio companies in order to de-risk and mature them up to the level at which they become attractive candidates for licensing, acquisition or IPO.

...



Aglaia is committed to defining the strategic directions of the companies it invests in, together with innovators and entrepreneurs. AglaiaIt offers portfolio companies support in designing research and development plans, ranging from early screening and animal feasibility studies through clinical studies.



Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 11 Feb 2019 9:09 pm
Edits made to:
Article (+5/-5 characters)

Article

Aglaia BioMedical Ventures has made 8 investments, has had 1 exit, which was MerusMerus.

Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 11 Feb 2019 9:09 pm
Edits made to:
Article (+11/-11 characters)

Article

Aglaia Biomedical Ventures B.V. was founded in 2003 by Mark Krul and Karl Rothweiler and is based in Bilthoven, the NetherlandsNetherlands. The firm invests in life science companies.

Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 11 Feb 2019 9:09 pm
Edits made to:
Article (+6/-6 characters)

Article

  • It invests in companies offering therapies for the prevention and cure of cancer. It usually invests in companies based in EuropeEurope.
Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 11 Feb 2019 9:09 pm
Edits made to:
Article (+16/-16 characters)

Article

Aglaia has a revenue of $1.4Million , focuses on oncology and invests in novel tools and technologies as well as components of contemporary drug developmentdrug development.

Carla Faraguna"Changed some wording to make it more neutral"
Carla Faraguna edited on 11 Feb 2019 9:09 pm
Edits made to:
Infobox (+2 properties)
Article (+99/-234 characters)
Related Topics (+2/-2 topics)

Article

Aglaia Biomedical Ventures B.V. was founded in 2003 by Mark Krul and Karl Rothweiler and is based in Bilthoven, the Netherlands.,Netherlands. theThe firm invests in life science companies.

...

Through its Oncology Funds I and II, Aglaia has invested in 12 early stage companies, 6 of which were founded by Aglaia. The experiencedAglaia team has been involved in the development of more than 100 oncology products. TheAglaia's goal is to have continuous strategic and operational involvement of the team with portfolio companies has contributed to a marked success rate in transitioning early-stage portfolio companiesorder to clinical-stage companies. By doing so, Aglaia has de-riskedde-risk and matured thesemature companiesthem up to the level at which they become attractive candidates for licensing, acquisition or IPO.

...

Aglaia is committed to defining the strategic directions of the companies it invests in, together with innovators and entrepreneurs. Aglaia bringsoffers hands-onportfolio experiencecompanies support in designing research and development plans, ranging from early screening and animal feasibility studies through clinical studies.

...
  • Foreseeable exit potential.

Infobox

Related Topics

Sergiu Miron
Sergiu Miron edited on 11 Feb 2019 8:05 pm
Edits made to:
Infobox (+8 properties)
Timeline (+8 events) (+376 characters)
Description (+104 characters)
Article (+3662 characters)
People (+9 rows) (+18 cells) (+249 characters)
Further reading (+15 rows) (+55 cells) (+3986 characters)
Documentaries, videos and podcasts (+1 rows) (+3 cells) (+226 characters)
Companies (+12 rows) (+12 cells) (+158 characters)
Categories (+1 topics)
Related Topics (+2 topics)
Topic thumbnail

Aglaia Biomedical Ventures

Aglaia is an oncology specialist investor which selects and matures early-stage breakthrough inventions.

Article

Aglaia Biomedical Ventures B.V. is a private equity and venture capital firm specializing in investments in incubation, startup, early stage, PIPEs, bridge financing, companies.

History

Aglaia Biomedical Ventures B.V. was founded in 2003 by Mark Krul and Karl Rothweiler and is based in Bilthoven, the Netherlands., the firm invests in life science companies.

The company, which currently has three funds under management, differs from other funds in that it focuses exclusively on oncology, as well as by getting involved at an early stage of technological development and through its hands-on management and efficient allocation of capital.

Aglaia has a revenue of $1.4Million , focuses on oncology and invests in novel tools and technologies as well as components of contemporary drug development.

Investments

Aglaia BioMedical Ventures has made 8 investments, has had 1 exit, which was Merus.

Aglaia has raised a total of $65M in a single venture fund, Aglaia Oncology Fund II. This fund was announced on Sep 18, 2014, and raised a total of $65M.

Aglaia Oncology Funds

  • Aglaia Oncology Fund B.V.
  • Aglaia Oncology Seed Fund B.V.
  • Aglaia Oncology Fund II B.V.

Through its Oncology Funds I and II, Aglaia has invested in 12 early stage companies, 6 of which were founded by Aglaia. The experienced team has been involved in the development of more than 100 oncology products. The continuous strategic and operational involvement of the team with portfolio companies has contributed to a marked success rate in transitioning early-stage portfolio companies to clinical-stage companies. By doing so, Aglaia has de-risked and matured these companies up to the level at which they become attractive candidates for licensing, acquisition or IPO.

Investment Criteria

  • Early-stage oncology drug development
  • Disruptive science with the potential to transform cancer diagnosis and therapy
  • Spread across different drug modalities (small molecules, biologicals, etc.) and drug development phases (from target discovery up to clinical development)
  • It focuses on investments in tools and technologies as well as components of contemporary drug development in biomedical companies in the field of oncology and in biotechnology companies.
  • It invests in companies offering therapies for the prevention and cure of cancer. It usually invests in companies based in Europe.
  • The firm typically invests up to EUR8 million (USD10.28 million) in the companies. It prefers to take an active role in the strategic and operational processes of its portfolio companies.
  • They derive their opportunities from research centers as well as from corporate spinouts then select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.

Strategy

Aglaia identifies opportunities in cancer research and, in partnerships with inventors and entrepreneurs, takes these opportunities to the next phase of technical and commercial development.

Aglaia is committed to defining the strategic directions of the companies it invests in, together with innovators and entrepreneurs. Aglaia brings hands-on experience in designing research and development plans, ranging from early screening and animal feasibility studies through clinical studies.

Technologies meeting the following criteria are eligible for further evaluation:

  • Fit within the focus area of oncology
  • Sustainable technological advantage
  • Above average business potential
  • Sound intellectual property protection or potential for patenting
  • Clearly definable milestones for development
  • Scientist's commitment and dedication
  • Foreseeable exit potential.

People

Name
Role
Related Golden topics

Alan Barge

Advisory Board



Angelique Hermeling

Office Manager



Eric van der Putten

Partner



Ernst Geutjes

Associate



Gabriele Dallmann

Advisory Board



Herman Spolders

Advisory Board



Karl Rothweiler

Co-founder, Partner



Kees Melief

Advisory Board



Mark Krul

Founder, Partner



Companies

Company
CEO
Location
Products/Services

Cristal Therapeutics







InterRNA Technologies







Inthera Bioscience







ISA Pharmaceuticals







Macrophage







Merus







Mimetas







Modra







ORCA Therapeutics







Sapreme Technologies







Somantix







Syntarga







Further reading

Title
Author
Link
Type

Concept buy Aquila inks immuno-oncology deal with Macrophage Pharma | FierceBiotech



Web

Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer | Aglaia Oncology Funds

Aglaia Oncology Funds

Web

Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline | Aglaia Oncology Funds

Aglaia Oncology Funds

Web

Dutch VC Aglaia BioMedical Ventures Invests in Swiss Biotech Inthera Bioscience



Web

InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting | Aglaia Oncology Funds

Aglaia Oncology Funds

Web

InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting | Aglaia Oncology Funds

Aglaia Oncology Funds

Web

Inthera Bioscience AG Expands Management Team with Seasoned Professionals and Secures €4.7 Million Second Tranche of €9.6 Million Series A Financing



Web

Inthera Bioscience AG expands management team with seasoned professionals and secures €4.7 million second tranche of €9.6 million Series A financing | Aglaia Oncology Funds

Aglaia Oncology Funds

Web

Inthera Bioscience wirbt 9,6 Mio. EUR ein



Web

ISA Pharmaceuticals' Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018 | Aglaia Oncology Funds

Aglaia Oncology Funds

Web

Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board | Aglaia Oncology Funds

Aglaia Oncology Funds

Web

Macrophage Pharma Appoints Dr Michael Moore as Chairman | Aglaia Oncology Funds

Aglaia Oncology Funds

Web

MIMETAS Secures 20 Million Dollar Series B Financing | Aglaia Oncology Funds

Aglaia Oncology Funds

Web

Modra Pharmaceuticals Expands Management Team and Provides Corporate Update | Aglaia Oncology Funds

Aglaia Oncology Funds

Web

The Good, the Bad and the Cancer-Fighting Macrophage



Web

Documentaries, videos and podcasts

Title
Date
Link

Business Analyst Positions (Industry Careers For PhDs Podcast) | Cheeky Scientist® | Industry Training For Intelligent People

22 June 2017

Infobox

Categories

Related Topics

Timeline

Merus

Series B - Merus

€21.7M

Aglaia Oncology Fund II

$65M

Inthera Bioscience

Seed Round - Inthera Bioscience

€3.4M

InteRNA Technologies

Series A - InteRNA Technologies

$10.5M

Macrophage Pharma

Series A - Macrophage Pharma

£9M

Cristal Therapeutics

Venture Round - Cristal Therapeutics

€12.8M

Inthera Bioscience

Series A - Inthera Bioscience

CHF10.5M

Mimetas

Series B - Mimetas

$28.9M

Edits on 7 Dec 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 7 Dec 2018 1:34 am
Edits made to:
Topic thumbnail

 Aglaia Biomedical Ventures

Aglaia is an oncology specialist investor which selects and matures early-stage breakthrough inventions.

No more activity to show.